Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Larimar Therapeutics, Inc.

Introduce lyophilized product into clinical development program

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
24 Mar 2025
Due
30 Jun 2025
Delivered
May 2025
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“agreed with Larimar’s plans to introduce the lyophilized product into our clinical development program in mid-2025”

What we found

Evidence strength A What the grades mean

The company began introducing the lyophilized product formulation into its open-label clinical study in May 2025, which is within the mid-2025 deadline.

  • A
    Larimar Therapeutics, Inc. 8-K filed 2025-08-14 Regulatory filing · published 14 Aug 2025 · retrieved 1 Oct 2026 · kept permanently by the SEC
    “In May 2025, Larimar began to introduce the lyophilized product formulation intended for commercialization into the open label study.” ✓ confirmed on the page

Market reaction: the shares moved +5.1% against the S&P 500 over the three sessions around the disclosure (13 Aug 2025 to 18 Aug 2025). What this measures

Checked 1 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Commercial launch
Indicative materiality
Medium rules
Action
Introduce
Deliverable
Lyophilized product
Language
Expected (“expects”, “plans”)
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2025-LRMR-003034 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.